Cargando…

Parabacteroides distasonis Properties Linked to the Selection of New Biotherapeutics

Dysbiotic microbiota is often associated with health issues including inflammatory bowel disease or ulcerative colitis. In order to counterbalance host disorder caused by an alteration in the gut composition, numerous studies have focused on identifying new biotherapeutic products (NBPs). Among the...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chamarande, Jordan, Cunat, Lisiane, Pavlov, Nadine, Alauzet, Corentine, Cailliez-Grimal, Catherine
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9572384/ https://www.ncbi.nlm.nih.gov/pubmed/36235828 http://dx.doi.org/10.3390/nu14194176

Ejemplares similares

In Silico Study of Cell Surface Structures of Parabacteroides distasonis Involved in Its Maintenance within the Gut Microbiota
por: Chamarande, Jordan, et al.
Publicado: (2022)

Surface Properties of Parabacteroides distasonis and Impacts of Stress-Induced Molecules on Its Surface Adhesion and Biofilm Formation Capacities
por: Chamarande, Jordan, et al.
Publicado: (2021)

Characterization of Two Parabacteroides distasonis Candidate Strains as New Live Biotherapeutics against Obesity
por: Cuffaro, Bernardo, et al.
Publicado: (2023)

Hypergravity disrupts murine intestinal microbiota
por: Alauzet, Corentine, et al.
Publicado: (2019)

Impact of a Model Used to Simulate Chronic Socio-Environmental Stressors Encountered during Spaceflight on Murine Intestinal Microbiota
por: Alauzet, Corentine, et al.
Publicado: (2020)

Parabacteroides distasonis ameliorates insulin resistance via activation of intestinal GPR109a
por: Sun, Yonggan, et al.
Publicado: (2023)

Diet Supplementation with NUTRIOSE, a Resistant Dextrin, Increases the Abundance of Parabacteroides distasonis in the Human Gut
por: Thirion, Florence, et al.
Publicado: (2022)

Parabacteroides distasonis uses dietary inulin to suppress NASH via its metabolite pentadecanoic acid
por: Wei, Wenchao, et al.
Publicado: (2023)

Polyclonal Aptamers for Specific Fluorescence Labeling and Quantification of the Health Relevant Human Gut Bacterium Parabacteroides distasonis
por: Xing, Hu, et al.
Publicado: (2021)

In Vitro Characterization of Gut Microbiota-Derived Commensal Strains: Selection of Parabacteroides distasonis Strains Alleviating TNBS-Induced Colitis in Mice
por: Cuffaro, Bernardo, et al.
Publicado: (2020)

Parabacteroides distasonis: intriguing aerotolerant gut anaerobe with emerging antimicrobial resistance and pathogenic and probiotic roles in human health
por: Ezeji, Jessica C., et al.
Publicado: (2021)

Pglyrp-Regulated Gut Microflora Prevotella falsenii, Parabacteroides distasonis and Bacteroides eggerthii Enhance and Alistipes finegoldii Attenuates Colitis in Mice
por: Dziarski, Roman, et al.
Publicado: (2016)

Indoleacrylic acid produced by Parabacteroides distasonis alleviates type 2 diabetes via activation of AhR to repair intestinal barrier
por: Liu, Deliang, et al.
Publicado: (2023)

Parabacteroides distasonis ameliorates hepatic fibrosis potentially via modulating intestinal bile acid metabolism and hepatocyte pyroptosis in male mice
por: Zhao, Qi, et al.
Publicado: (2023)

Classification of Parabacteroides distasonis and other Bacteroidetes using O- antigen virulence gene: RfbA-Typing and hypothesis for pathogenic vs. probiotic strain differentiation
por: Bank, Nicholas C., et al.
Publicado: (2022)

Bone marrow vs Wharton’s jelly mesenchymal stem cells in experimental sepsis: a comparative study
por: Laroye, Caroline, et al.
Publicado: (2019)

Clinical-grade mesenchymal stem cells derived from umbilical cord improve septic shock in pigs
por: Laroye, Caroline, et al.
Publicado: (2018)

Complete Genome Sequence of a Parabacteroides distasonis Strain (CavFT hAR46) Isolated from a Gut Wall-Cavitating Microlesion in a Patient with Severe Crohn’s Disease
por: Yang, Falong, et al.
Publicado: (2019)

Parabacteroides pacaensis sp. nov. and Parabacteroides provencensis sp. nov., two new species identified from human gut microbiota
por: Benabdelkader, S., et al.
Publicado: (2020)

In vivo selection of novel biotherapeutics
por: Ruozi, Giulia, et al.
Publicado: (2015)

Antibiotic-Free Selection in Biotherapeutics: Now and Forever
por: Mignon, Charlotte, et al.
Publicado: (2015)

Relations of Psychosocial Factors and Cortisol with Periodontal and Bacterial Parameters: A Prospective Clinical Study in 30 Patients with Periodontitis Before and After Non-Surgical Treatment
por: Dubar, Marie, et al.
Publicado: (2020)

Algorithm for rational use of Film Array Pneumonia Panel in bacterial coinfections of critically ill ventilated COVID-19 patients
por: Novy, Emmanuel, et al.
Publicado: (2021)

“Stapling” scFv for multispecific biotherapeutics of superior properties
por: Boucher, Lauren E., et al.
Publicado: (2023)

Advances in the Development of Biotherapeutics
por: Oliveira, Pedro H., et al.
Publicado: (2015)

Integrated BioTherapeutics
por: Aman, M. Javad
Publicado: (2018)

Parabacteroides bouchesdurhonensis sp. nov., a new bacterium isolated from the stool of a healthy adult
por: Yimagou, E.K., et al.
Publicado: (2019)

Echinococcus granulosus Infection Results in an Increase in Eisenbergiella and Parabacteroides Genera in the Gut of Mice
por: Bao, Jianling, et al.
Publicado: (2018)

A269 THE MODULATION OF INTESTINAL INFLAMMATION BY PARABACTEROIDES GOLDSTEINII IN MURINE MODELS OF COLITIS
por: Gerkins, C, et al.
Publicado: (2023)

A271 THE MODULATION OF INTESTINAL INFLAMMATION BY PARABACTEROIDES GOLDSTEINII IN EXPERIMENTAL MURINE COLITIS
por: Gerkins, C, et al.
Publicado: (2023)

Trends in industrialization of biotherapeutics: a survey of product characteristics of 89 antibody-based biotherapeutics
por: Martin, Kyle P., et al.
Publicado: (2023)

Parabacteroides massiliensis sp. nov., a new bacterium isolated from a fresh human stool specimen
por: Bellali, S., et al.
Publicado: (2019)

Posttranslational Modifications and the Immunogenicity of Biotherapeutics
por: Jefferis, Roy
Publicado: (2016)

The Development Pathway for Biosimilar Biotherapeutics
por: Zarbin, Marco
Publicado: (2020)

The Emerging Biotherapeutic Agent: Akkermansia
por: Kalia, Vipin Chandra, et al.
Publicado: (2021)

Editorial: Characterization of biotherapeutic products
por: Rathore, Anurag S., et al.
Publicado: (2022)

Streamlined Genetic Manipulation of Diverse Bacteroides and Parabacteroides Isolates from the Human Gut Microbiota
por: García-Bayona, Leonor, et al.
Publicado: (2019)

Docosahexaenoic Acid Promotes Cd Excretion by Restoring the Abundance of Parabacteroides in Cd-Exposed Mice
por: Liao, Jianzhen, et al.
Publicado: (2023)

A New Look at the Genus Solobacterium: A Retrospective Analysis of Twenty-Seven Cases of Infection Involving S. moorei and a Review of Sequence Databases and the Literature
por: Alauzet, Corentine, et al.
Publicado: (2021)

Co-detection of SARS-CoV-2 and other respiratory pathogens: Lessons from the field to face the second wave
por: Muggeo, Anaëlle, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_tl29o4h4tjp3e0qf5c6n9babm2